Process for preparing recombinant eglin, protease inhibitor

US6342373B1 · kind B1 · utility

Assignee

• UCP Gen-Pharma AG · CH

Inventors

• Hans Rink · Riehen, CH
• Manfred Liersch · Riehen, CH
• Peter Sieber · Reinach, CH
• Werner Rittel · Basel, CH
• François Meyer · Zürich, CH
• Ursula Seemuller · Munich, DE
• Hans Fritz · Höhenkirchen-Siegertsbrunn, DE
• Walter Marki · Möhlin, CH
• Sefik Alkan · Riehen, CH

Key dates

• Filing date: May 24, 1991
• Grant date: Jan 29, 2002
• Expiry date: May 24, 2011

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.